Retatrutide Versus Tirzepatide in T2DM: Indirect Network Meta-Analysis of Sparse Data
This network meta-analysis offers the first indirect comparison of retatrutide and tirzepatide in type 2 diabetes, but retatrutide estimates rest on one phase 2 trial and two small phase 1b studies, so pharmacists should treat it as a hypothesis-generating framework.
Retatrutide outperforms in weight reduction for diabetes management.
Type 2 diabetes mellitus often requires enhanced glycemic control strategies, making novel agents like retatrutide highly relevant. Retatrutide 8 mg significantly reduced body weight (-13.03 kg) and waist circumference (-8.63 cm), with both agents improving HbA1c and fasting insulin levels. The findings suggest that retatrutide may offer superior weight loss benefits compared to existing treatments, but further clinical adoption requires more direct comparative studies. Retatrutide shows promise for enhanced weight management in type 2 diabetes compared to current incretin therapies.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Tereshchenko A, Garay Gálvez B, Tello JA
Citation:Tereshchenko A, Garay Gálvez B, Tello JA Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus. Therapeutic advances in endocrinology and metabolism. 2026;19:20420188261474093. doi:10.1177/20420188261474093